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1. Introduction 
Polymer nanoparticles with targeting capability have been 
widely developed as promising drug delivery vehicles [1–3]. 
Enhanced disease tissue accumulation and cellar internal-
ization are two basic properties for nanoparticles to have 
achieved target delivery [4–6]. Tumor accumulation is usu-
ally achieved through a long circulation time and the perme-
ability and retention (EPR) effect, which allows nanoparticles 
to penetrate through the leaky tumor vasculature other than 
normal tissue in a passive way [7,8]. Cellular internalization 
is another important step for the accumulated nanoparticles 
to have efficacious therapeutic results, which is associated 
with the size and surface properties of nanoparticles [9]. The 
internalization process is usually enhanced by grafting tar-
geting ligands or the positive charged surfaces of nanopar-
ticles, since these decorations on the particle surfaces can 
induce the ligand-receptor interactions or electrostatic in-
teractions with cell membranes [10]. It has been discovered 
that positive charged or ligand decorated nanoparticles are 
generally easy to be recognized and cleared by the reticu-
loendothelial system (RES), which can significantly reduce 
the circulation time and thus deteriorate the accumulation 
of nanoparticles on tumor sites [11]. Prolonged circulation 
time and enhanced accumulation can be achieved by adopting 
negatively charged nanoparticles modified with hydrophilic 
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Abstract 
The mutually conflicting surface charge requirements for nanoparticles to have long circulation and good cell affin-
ity have made the development of polymer nanoparticles for controlled drug delivery fall into a dilemma. In order to 
solve this problem, the first attempt has been made in this work to develop vancomycin loaded composite nanoparticles 
with a novel chitosan core and poly (lactide-co-glycolide) (PLGA) shell structure and with both pH-responsive and sur-
face charge switchable properties. Spherical composite nanoparticles have been successfully fabricated through a mod-
ified emulsion-gelation method with a controllable size (316–573 nm), surface charge (–27.6–31.75 mV) and encapsu-
lation efficiency up to 70.8%. The dilemma can be avoided by tailoring the composite nanoparticles with the specially 
designed core-shell structure to be negative charged in the beginning and switch to positive charge later on. The nega-
tive charge of particles can be switched to positive charge gradually as the erosion of biodegradable polymer shells and 
exposure of the positive charged chitosan core. The formed chitosan hydrogel exhibited multi-layer structures, which 
were primarily influenced by chitosan concentration. Influences of the chitosan gelation behaviors on the properties of 
the composite nanoparticles in response to different chitosan and NH3 concentrations have also been studied. Release 
rate decreased significantly with increasing chitosan concentration. With the introduction of the chitosan, the increase 
in drug release rate by orders of magnitude was observed for the samples immersing in the phosphate buffer saline so-
lution of lower pH value proving a pH responsive release property. Drug release profiles of the composite nanoparti-
cles were divided into fast release stage and slow release stage. The fast release stage was well described by a modified 
first-order kinetic model; while the slow release stage was fitted well with the classical first-order release kinetic model. 
All the presented results make the proposed composite nanoparticles a promising system for controlled drug delivery. 
Keywords: Polymer-matrix composites (PMCs), Nano-structures, Particle-reinforcement, Microstructures, Chitosan, 
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groups, such as PEG, on their surfaces [12]. However, the neg-
ative charge and hydrophilic groups could hinder the inter-
actions between nanoparticles and cell membrane, which is 
unfavorable for cellular interaction [13]. 
In order to solve this dilemma, nanoparticles with switch-
able surface properties are desirable. Nanoparticles are re-
quired to exhibit a negative charge before reaching tumor 
sites. After their accumulation on the tumor tissues, the 
nanoparticles are required to become positively charged in 
order to accelerate the cellular internalization. To realize this 
delivery strategy, some attempts have been employed to de-
velop surface charge-switchable nanoparticles [7]. Hung et 
al. [14] developed a pH-triggered surface charge-switchable 
poly (lactide-co-glycolide) (PLGA) nanoparticles for drug deliv-
ery by grafting pH-responsive N-acetyl histidine modified d-α-
tocopheryl polyethylene glycol succinate chains on the surface 
of the PLGA nanoparticles. These modified PLGA nanoparticles 
changed to be positively charged after being triggered by acid 
tumor extracellular environment due to the enhanced proton-
ation of the grafted functional groups. In another study, nega-
tively charged 2, 3-dimethylmaleic anhydride (DMMA) groups 
were introduced to shield the positively charged nanoparticles 
by binding them with the amino groups on the particle sur-
faces [15]. The DMMA groups detached from the amino groups 
responding to the tumor extracellular acidity would recover to 
become positively charged. Another strategy to achieve sur-
face charge switching is the adoption of the Zwitterionic sur-
faces [16–18]. A variety of pH-responsive zwitterionic groups 
have been developed for the surface modification of nanopar-
ticles, such as carboxybetaine [16], phosphorylcholine [17] and 
alkoxyphenyl acylsulfonaminde [18]. These functional groups 
are capable to switch from negative or neutral charges to pos-
itive charges at acidic environments. Thus, this type of surface 
modification has been proved to be an effective route to equip 
nanoparticles with a surface charge switching property. How-
ever, these surface modification processes are usually com-
plex and may deteriorate the nanoparticles in certain extend. 
PLGA, an American food and drug administration (FDA) 
approved polymer, has attracted increasing attentions as the 
primary composition of nanoparticles for drug delivery pur-
pose, because of its degradability and controllable drug re-
lease profile [1,8,19–21]. However, the negatively charged sur-
faces of PLGA based nanoparticles render them inappropriate 
to have effective targeting effects. Chitosan, a natural occur-
ring biodegradable polymer acquired from the deacetylation 
of chitin, has been widely adopted in industrial and pharma-
ceutical applications, because of its intrinsic properties such 
as biocompatibility, biodegradability, bacteriostatic effect and 
abundance in nature [1,22–25]. The positive charges of chito-
san based nanoparticles are beneficial for cell affinity and in-
ternalization. However, the circulation time is compromised. 
In this study, with motivation by the merits of both poly-
mers, we have designed a novel and facile strategy for fabri-
cating effective pH-responsive and switchable surface charged 
chitosan hydrogel/PLGA core-shell composite nanoparticles for 
drug delivery. A model drug, vancomycin HCl, was incorpo-
rated into the pH-responsive chitosan hydrogel core which was 
then encapsulated by the PLGA shell through a one-step emul-
sion gelation method. With the developed core-shell structure, 
the positively charged chitosan could be physically shielded. 
Following the erosion of the polymer shell and the expo-
sure of chitosan core, the surface properties of the composite 
nanoparticles were switched from negative to positive charges. 
Gelation behaviors of the chitosan solution in response to the 
concentration of chitosan and alkali were studied. Influences 
of key fabrication parameters on the particle size, drug encap-
sulation efficiency, surface charge and drug release kinetics of 
the composite nanoparticles were all investigated. 
2. Material and methods 
2.1. Materials 
Poly (lactic-co-glycolic acid) (PLGA) (Mw: ~30 kDa) and Poly 
((D, l-lactic acid-co-glycolic acid)-block-ethylene glycol) 
(PLGA-PEG) (Mw: ~11 kDa) were obtained from the Jinan Dai-
gang Biomaterial Co., Ltd. Dichloromethane (DCM), acetate 
acid and NH3 solution were purchased from the Merck & Co. 
Polyvinyl alcohol (Mw: ~23 kDa) and tetraethylorthosilicate 
(TEOS) were acquired from the Sigma-Aldrich. Vancomycin 
HCl (VCM) was obtained from the Amresco. Chitosan (Mw = 
~500 kDa, deacetylation degree, > 95%) was purchased from 
the Heifei Bomei Biotechnology Co., Ltd. 
2.2. Fabrication of drug loaded chitosan/PLGA composite 
nanoparticles 
The proposed composite nanoparticles were prepared through 
a modified gelation emulsion method [26]. Briefly, 30 mg of 
VCM was dissolved into 1 ml of chitosan solution. Chitosan so-
lutions of different concentration (0.5%–2%) were prepared 
by dissolving the chitosan powder into acetate acid aqueous 
solution of the same concentration. 1 ml of the chitosan-VCM 
solution and 0.1 ml of NH3 solution were ultrasonically emul-
sified into 5 ml of PLGA/DCM solution separately to form two 
emulsions. The PLGA/DCM solution was prepared by dissolv-
ing PLGA and PEG-PLGA with a weight ratio of 3: 2 into 5 ml 
of DCM. Both of the emulsions were blended and sonicated for 
3 min to give a primary emulsion. The primary emulsion was 
then ultrasonically dispersed into 22 mL of 0.5% PVA solution 
to form the secondary emulsion which was then agitated for 
3 h to evaporate all the organic solvent. The nanoparticle sus-
pension was centrifuged at 12000 rpm for 30 min. The super-
natants were kept for drug concentration analysis. The com-
posite nanoparticles were obtained after washing and drying 
the precipitated solids. 
2.3. Characterization 
The morphologies and structures of the composite nanoparti-
cles were examined using scanning electron microscopy (SEM) 
(JEOL JSM-6490) and STEM (JEOL JEM-2100F). Specimens for 
SEM were treated by coating a gold layer. Compositional infor-
mation on the nanoparticles was obtained by Fourier Trans-
form Infrared (FTIR) spectrometry (Thermo Scientific Nicolet 
IS50). The size and zeta potential of the nanoparticles were 
measured by a Zetasizer Nano ZS (Malvern Instruments, Mal-
vern, U.K.) instrument. 
2.4. Determination of encapsulation efficiency 
The concentration of VCM in the supernatant was identified 
by measuring its absorbance using the UV spectrophotometry 
at 280.5 nm. A standard curve, that was used to calibrate the 
relationship between the drug concentration and UV absor-
bance, was prepared using a drug concentration of 0.6–0.032 
mg/ml in 0.5% of PVA. The standard curve of drug concen-
tration in response to UV absorbance was determined to be y 
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= 0.16672x – 0.00421 with a correlation factor R2 of 0.999 in 
regression analysis. The encapsulation efficiency (EE) of the 
vancomycin in the nanoparticles was determined by identi-
fying the concentration of the nonencapsulated free drug in 
the supernatant after centrifugation of the nanoparticle sus-
pension at 12000 rpm for 30 min. The EE of the  drug loaded 
nanoparticles was calculated by using the following equation: 
Encapsulation Efficiency (%) 
          
=
 Total drug amount – Free drug amount 
                             Total drug amount                     
× 100%
   
2.5. In vitro drug release 
An appropriate amount of nanoparticles containing 3 mg of 
VCM were dispersed into 40 ml of phosphate buffer solution 
(PBS) (pH = 7.2 ± 0.2) in a 50 ml tube with a cap. The tube 
was shaken at 100 cycles/min in a gas bath shaker with a con-
stant temperature of 37.0 ± 0.2 °C 4 ml of dissolution medium 
was withdrawn from each tube at a fixed time interval. Af-
ter centrifugation at 12000 rpm for 10 min, 2 ml of superna-
tants of the collected dissolution medium samples were fil-
tered through 0.22 μm-membrane before analyzing the drug 
concentration via UV/vis spectrophotometry at 280.5 nm. All 
the dissolution mediums were added back to the correspond-
ing tube after the completion of analysis. 
3. Results and discussion 
3.1. Size, morphology, encapsulation efficiency and zeta po-
tential of the composite nanoparticles 
Composite nanoparticles prepared with 1% of chitosan and 
1.5% NH3 concentration in this study were spherical as con-
firmed in the SEM image in Fig. 1(a), and their particle size 
distribution was acceptable with a low polydispersity index 
of 0.262. For the composite nanoparticles prepared with 1% 
of chitosan concentration, their size increases up to 413 nm 
with increasing NH3 concentration from 0.75% to 3%, while 
there is a decrease in the particle size up to 367 nm for the 
NH3 concentration of 3%–12% as shown in Fig. 2. From Fig. 3, 
the particle size increases from 404 to 573 nm with decreas-
ing chitosan concentration from 2% to 0.063% for a constant 
ratio of chitosan to NH3 concentration. It can also be observed 
from Fig. 2 that the particle size and surface charge (zeta po-
tential) of the composite nanoparticles rise with the NH3 con-
centration before 3% NH3 concentration. The particle size ex-
hibits only a mild decrease when the NH3 concentration is 
above 6%, which is due to the formation of more compact hy-
drogel in the presence of the extra alkali. With different chi-
tosan and NH3 concentrations, encapsulation efficiency (EE) 
and Zeta potential also vary from 56.1% to 70.8% and –27.6–
31.75 mV respectively (Figs. 2 and 3). All these results are fur-
ther discussed in the following sections. 
3.2. FT-IR analysis 
The comparative FI-IR spectrum of PLGA, chitosan, PEG-PLGA 
and composite nanoparticles is presented in Fig. 4. The strong 
peak at 1755 cm–1 is assigned to the stretching vibration of the 
ester C=O of PLGA and PEG-PLGA. The asymmetric and sym-
metric stretching vibration of the C-H bonds of –CH3 groups 
of the PLGA and PEG-PLGA are characterized by the peaks at 
Fig. 1. Composite nanoparticles prepared with 1% of chitosan and 1.5% NH3 concentration (Average diameter: 334 nm, Polydispersity in-
dex: 0.262), (a) SEM image, and (b) particle size distribution.  
Fig. 2. Comparison of composite nanoparticles prepared with dif-
ferent NH3 concentration and a constant 1% chitosan concentration. 
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3003 cm–1 and 2955 cm–1 respectively. The peak at 2883 cm–1 is 
due to the C–H stretching vibration of –CH2. The characteristic 
peaks at 1645 cm–1 and 1598 cm–1 are the N-H bending vibration 
of the primary and secondary amides of chitosan respectively, 
confirming the presence of chitosan in the composite nanopar-
ticles. The stretching vibrations of N–H and O–H groups of chi-
tosan are expressed as the wide and sharp peak at 3480 cm–1 in 
Fig. 4 (d). The peaks at ~3480 cm–1 of the PLGA and PEG-PLGA 
are associated with the –OH stretching vibration. 
3.3. Investigation on gelation process of chitosan solution 
The chitosan solution in this study was physically gelled by 
the exposure to alkali, leading to the entanglement of the chi-
tosan molecular chains. Referring to our fabrication process, 
the chitosan solution and NH3 solution were firstly dispersed 
into the individual PLGA/DCM solution. The gelation of the 
chitosan solution droplets was triggered by their collisions 
with the droplets of NH3 solution. The collisions may occur 
between two different droplets or among multiple droplets 
as confirmed in TEM image (Fig. 5 (a) & (b)). After collision, 
the NH3 solution droplets start to merge with the chitosan 
solution as shown in Fig. 5(c). According to Fick’s first law, 
the solute (NH3) diffused from a high concentration region 
(NH3 droplet) to a low concentration region (chitosan drop-
let) across a concentration gradient. 
This gradient diffusion of the alkali solution has been found 
to enable formation of multilayer chitosan hydrogel instead of 
forming cross-linked gel simultaneously as reported in liter-
ature [27]. According to their study, the gelation speed of the 
chitosan solution decreased while the alkali solution diffused 
from the top to the bottom, leading to formation of multilayer 
chitosan hydrogel with different structure. A primary chito-
san hydrogel layer with a smooth and compact structure was 
formed promptly on the interface once in contact with the al-
kali solution. Following the continuous diffusion of alkali so-
lution to the bottom, an oriented layer, which is characterized 
by a diffusion direction oriented structure with minor poros-
ity, was formed. In this layer, some of the chitosan molecular 
chains was deprotonated and embed in the upper unit, while 
the other part of the chains were relaxed and able to inter-
act with other unrestricted protonated molecular chains. Due 
to the diffusion of the alkali solution, the relaxed part of the 
molecular chains was restricted and the chitosan molecular 
chains interacting with this part of the chains was therefore 
aligned. This orientation has been found to occur only in the 
high chitosan concentration. It was also found that there was 
a critical chitosan concentration below which the orientation 
layer could not be formed. The viscosity of the chitosan so-
lution for its concentration above and below the critical val-
ues was found to vary significantly. This critical chitosan con-
centration was found to be reduced with increasing molecular 
weight of the chitosan. A highly porous layer was formed in 
the highly reduced alkali solution or in the chitosan solution 
with the concentration below its critical value, which was con-
sidered to be isotropic. 
In the current study, the alkali (NH3) droplet diffused from 
its center towards outward. The generated chitosan hydro-
gel core was assumed to have a multi-layer structure follow-
ing the similar gelation process as discussed above. As il-
lustrated in Fig. 6, there should be a compact, oriented and 
porous structure and unreacted chitosan along the diffusion 
direction of the NH3 droplets. Thus, the gelation behaviors 
of the chitosan solution and the properties of the composite 
nanoparticles became highly dependent on the concentration 
of the chitosan and NH3 solutions. 
3.4. Control and influences of the gelation behavior of 
chitosan 
The critical polymer concentration has been discovered to be 
0.56 wt% for the chitosan of molecular weight of 200 kDa 
as reported in literature [27]. Since the molecular weight of 
the chitosan in the present study is about 500 kDa, the criti-
cal concentration should be lower than 0.56 wt%. A series of 
the chitosan concentrations ranging from 0.0625 to 2.0 wt% 
were therefore adopted to determine its critical concentration, 
and explore the properties changes of the composite nanopar-
ticles around this critical concentration. From Fig. 3, the crit-
ical chitosan concentration was found to be 0.37 wt%, as re-
flected from the most remarkable change of the particle size 
over other properties. It can also be observed from this figure 
that the particle size exhibits an insignificant decrease with 
increasing chitosan concentration above the critical value, but 
increases significantly for the chitosan concentration below 
the critical value. As discussed in Section 3.3, most of the chi-
tosan gel had a highly porous structure, because the oriented 
layer was rarely formed when the chitosan solution was be-
low the critical value. Moreover, this porous structure could 
encapsulate and prevent the outflow of more water molecules 
Fig. 4. FT-IR spectra of (a) PEG-PLGA, (b) PLGA, (c) composite 
nanoparticle and (d) chitosan.  
Fig. 3. Comparison of composite nanoparticle prepared with dif-
ferent chitosan concentration at a constant ratio (1:3) of chitosan 
to NH3 concentration.  
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as well as drug molecules as compared with the less porous 
oriented layer. This result has been confirmed by the increas-
ing tendency of EE with the decrease of chitosan concentra-
tion, especially when the concentration is below the critical 
value (Fig. 3). Surface properties of the composite nanoparti-
cles, in terms of surface charge, exhibited a proportional re-
lationship with the chitosan concentration, which is primarily 
ascribed to the reducing content of positively charged chito-
san in the nanoparticles. It was because the surface charge of 
the nanoparticles changed from a negative to positive one due 
to the introduction of the chitosan as the core material. This 
charge change may result from partially protonated chitosan 
molecular chains tending to penetrate through the polymer 
shell and influence the charge balance of the particles; while 
the deprotonated part of the chitosan chains was embedded 
in the hydrogel matrix of the particle core. The amount of the 
added alkali (NH3) solution was just enough to neutralize ac-
etate acid in each formulation of the samples in Fig. 3. The 
protonated chitosan molecules at the surface of hydrogel core 
were supposed to be deprotonated by the addition of extra al-
kali, which could therefore change the charge of the particles. 
To verify this assumption, different NH3 concentrations were 
adopted for preparation of composite nanoparticles contain-
ing 1% chitosan solution. 
Referring to the results depicted in Fig. 2 and described in 
section 3.1, 3%NH3 concentration was just enough to cause 
gelation of the nanoparticles by neutralizing all the acid in 
the 1% chitosan concentration. It was because the chitosan 
solution could not be gelled or deprotonated completely when 
the NH3 concentration is below 3%). The unrestricted proton-
ated (unreacted) chitosan molecules tended to escape from 
the nanoparticles under sonication during fabrication process, 
leading to the reduction of particle size with decreasing NH3 
concentration. The surface charge of the composite nanopar-
ticles switched from a positive to a negative charge one as in 
Fig. 2 when the extra NH3 (with concentration > 3%) was in-
troduced. This result confirmed the previous assumption that 
the protonated part of the chitosan could be deprotonated and 
restricted when the extra alkali was used. From Fig. 2, a fur-
ther increase of the NH3 concentration (>3%) would lead to 
formation of less unrestricted and protonated chitosan mo-
lecular chains. The impact of the positively charged chitosan 
on the negatively charged polymer shell was therefore min-
imized. Zeta potential of composite nanoparticles decreases 
slightly in a lower NH3 concentration (<3%) as in Fig. 2 ow-
ing to the leakage of the protonated and free chitosan mole-
cules during fabrication. The composite nanoparticles with a 
negative charge can be switched to possess a positive charge, 
Fig. 5. Images and schematic formation of chitosan hydrogel core during fabrication, (a) & (b): TEM images of composite nanoparticles. 
(c) Schematic integration and diffusion of NH3 into chitosan droplets.  
Fig. 6. Schematic chitosan core structure.  
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when the cores of the drug loaded chitosan were exposed to 
the body fluid after erosion of its polymeric shells. This equips 
the nanoparticles with advantageous properties of both long 
circulation time and good cell affinity. 
3.5. In vitro drug release kinetic 
Drug release profiles of composite nanoparticles prepared 
with chitosan concentrations ranging from 0.25% to 2% are 
presented in Fig. 7. Drug releases within 24 h and 2 weeks 
vary from 83% to 48% and 95%–68% respectively with in-
creasing chitosan concentration up to 2%. Because of the core-
shell structure of the composite nanoparticles, the drug mole-
cules released from the chitosan core were influenced by the 
erosion of polymeric shells, degradation of the chitosan, dis-
solution and diffusion of the drug molecules. The drug release 
profiles of the composite nanoparticles were approximated by 
two stages: an initial fast release stage within the first 24 h 
and a subsequent sustained slow release stage. The first re-
lease stage resulted from a combinational effect of dissolution 
and diffusion of the drug molecules that were embedded in the 
polymeric shell and entrapped in the porous layer of the chi-
tosan core. The release profiles of the first stage release re-
flected the diffusion controlled dissolution of the embedded 
drugs. After most of the drug molecules embedded in poly-
meric shell and the porous structure of the chitosan hydrogel 
core were released within the first 24 h, the release rate of the 
entire system became reduced significantly. According to the 
characteristics of the fast release stage, the cumulative release 
at any time during the first 24 h could be approximated to be 
the upper limit (A) of the fast release stage. This release be-
havior could be characterized by the following equation de-
veloped based on the first-order kinetics [28] modified with 
an additional upper limit, A. 
                                      Mt 
M∞ 
= A (1 – e –kt )                             (1) 
where Mt and M∞ are defined as fractions of the released 
drugs at time t and infinite time respectively; k is the release 
rate constant. This modified first order kinetic would become 
classic first-order kinetic when A is equal to 1. Therefore, 
equation (1) is applied to characterize the situations when A 
is not equal to 1. 
Regression analysis of the data was performed using equa-
tion (1) and the results are shown in Table 1. The release rate 
constant (k) increases gradually with reducing chitosan con-
centration, especially when the concentration is lower than 
0.5% (Fig. 8). This result is coincident with the relationship 
between the chitosan concentration and formation of the po-
rous layer as described in Section 3.3. Comparison between 
the predicted and experimental values of A is presented in Ta-
ble 1 and Fig. 9. The relative errors of between predicted and 
experimental A values were found to be smaller than 7%, with 
no significant difference as confirmed in a student t-test with 
p < 0.05. All these analysis results have confirmed the effec-
tiveness of equation (1) in describing the drug release kinet-
ics of the composite nanoparticles in the fast release stage. 
Fig. 7. Drug release profiles of composite nanoparticles with various chitosan concentrations under different stages. (a) the entire drug re-
lease stage, (b) the fast release stage (≤24 h), and (c) the slow release stage (>24 h).  
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The following slow release stage may be ascribed to the 
combinational effects of the erosion of polymer shells, ero-
sion of chitosan matrices, dissolution and diffusion of the drug 
molecules encapsulated in the oriented and compact struc-
tures of the chitosan hydrogel cores. Erosion of the poly-
mer shells and chitosan matrices were assumed to be the 
dominating effects, because the drug molecules encapsulated 
in the chitosan cores, before releasing to the external PBS, 
were required to penetrate through the eroded polymer shell 
and chitosan matrices. To investigate this combinational ef-
fect, several release kinetics were investigated. Drug release 
from biodegradable PLGA are usually characterized by the 
classical first-order kinetics considering the hydrolytic deg-
radation behaviors of polymers [28], which can be expressed 
by equation (1) with A = 1. 
Drug released from chitosan nanoparticle was found to be 
best fitted with the Higuchi square root of time model [29,30]: 
( Mt )2 = kt                                      (2)                                          M∞  
As shown in Fig. 7(c), the release profiles exhibit a linear 
relationship, which is usually described by the zero order 
release kinetics [31]: 
                                            Mt 
M∞ 
= kt                                      (3) 
To evaluate the effectiveness of these models, regression 
analysis was performed by fitting the data by various the ki-
netics models. Correlation coefficients (R) of the aforesaid 
models are compared in Table 2. The first order kinetics show 
the best fit with the cumulative release data for the slow re-
lease stage. From Fig. 10, the release rate constant (k) at 
0.25% chitosan concentration is 5 times greater than that of 
higher chitosan concentration due to the absence of the ori-
ented structure in the chitosan with a concentration lower 
than its critical value of 0.37%. 
Influences of external stimuli, in terms of pH value, on 
drug release profiles of the drug loaded composite nanopar-
ticles were evaluated by immersing the samples in PBS solu-
tion with different pH values. As shown in Fig. 11, a significant 
increase for the drug release rate of the nanoparticles is ob-
served for the samples in the PBS solution of lower pH value. 
The samples in the PBS solution of pH = 1.2 exhibits the fast-
est release rate and realize 100% release in 5 days; but the 
sample in the PBS solution of pH = 4.8 shows a complete re-
lease in 14 days. Regression analyses of the fast release stage 
and slow release stage were performed by using the modified 
first-order kinetic (As1) and the classical first-order kinetic 
(A = 1) equations, respectively (Table 3). For the fast release 
stage, a relatively mild increase in the release rate with reduc-
ing pH values is observed, because the erosion of polymeric 
shell in this stage was relatively less impacted by the pH value 
of PBS solution. For the slow release stage, the increase in the 
release rate becomes more significant as shown in Fig. 11(c), 
because the primary effect of the second stage release is the 
swelling and degradation behavior of the chitosan which is 
significantly influenced by the pH value. As the chitosan mo-
lecular chains were protonated in a lower pH solution, it led 
to the swelling and dissolution behaviors, and contributed to 
the fast release rate of the encapsulated drugs.  
Fig. 8. Release rate constants (k) for the first release stage with dif-
ferent chitosan concentrations (pH = 7.4).  
Fig. 9. Comparison of predicted and experimental release upper 
limit (A) values.  
Table 2. Correlation coefficient (R) of different release kinetic 
models for the slow release stage. 
Model  2.00%  1.00%  0.50%  0.25% 
Zero order 0.897  0.985  0.974  0.975 
Classical First Order (A = 1)  0.913  0.989  0.980  0.995 
Higuchi  0.906  0.987  0.976  0.978  
Table 1. Correlation coefficient (R), release rate constant and release upper limit of the modified kinetic model (As1) for first release stage. 
Parameter  2.00%  1.00%  0.50%  0.25% 
Correlation coefficient (R)  0.998  0.996  0.999  0.999 
K  0.145 (±0.0078)  0.144 (±0.014)  0.220 (±0.0085)  0.360 (±0.020) 
Predicted A  50.57%  71.39%  72.12%  81.33% 
Experimental A  48%  67%  72%  83%  
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4. Conclusion 
Surface charge switchable and pH responsive vancomycin 
loaded chitosan/polymer composite nanoparticles of a novel 
core-shell structure with an adjustable size range of 316–573 
nm and a drug encapsulation efficiency up to 70.8% have been 
successfully fabricated in the first attempt via a modified ge-
lation emulsion method. Surface charges of the particles could 
be controlled from –27.6–31.75 mV by adjusting the concen-
trations of the chitosan and NH3 solutions. The conflicts of 
long circulation time and good cell affinity could be avoided 
by developing negatively charged composite nanoparticles, be-
cause the exposure of the chitosan core after degradation of 
the polymer shells could switch the nanoparticles to possess 
a positive charge. The generated chitosan hydrogel core ex-
hibited multi-layer structures with a combination of compact 
layer, oriented layer and highly porous layer along the diffu-
sion direction of the incorporated NH3 solution, which have 
been found to influence the properties of composite nanopar-
ticles. Formation of multilayer chitosan hydrogel was found to 
be related to the concentration of chitosan solution. The crit-
ical chitosan concentration was confirmed to be 0.37%, be-
low which no oriented structure was formed. Moreover, in-
fluences of the gelation behaviors of chitosan solution on the 
size, zeta potential, encapsulation efficiency as well as drug 
release were well investigated. Drug release profiles of the 
nanoparticles were classified into a fast release stage (≤24 
h) and a slow release stage (>24 h). The fast release stage 
was caused by the diffusion controlled dissolution behaviors 
Table 3. Regression results of samples in PBS solutions with differ-
ent pH values. 
Parameter  pH = 7.4  pH = 4.8  pH = 1.2 
Fast release stage  0.996  0.981  0.985 
K  0.144 (±0.014)  0.157 (±0.030)  0.207 (±0.034) 
Slow release stage  0.989  0.989  1 
K (10–4)  6.07 (±0.46)  66.5 (±5.62)  233.2  
Fig. 10. Release rate constants (k) for the slow release stage with 
different chitosan concentrations (pH = 7.4).  
Fig. 11. Drug release profiles of composite nanoparticles with 1% chitosan concentrations in PBS of different pH values under different 
stages. (a) the entire drug release stage, (b) the fast release stage (≤24 h), and (c) the slow release stage (>24 h).    
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of drug molecules embedded in the polymeric shell and the 
porous structure of the chitosan core, which exhibited mod-
ified first-order release kinetics. The slow release stage was 
attributed to the erosion of polymer shells and chitosan cores 
of the nanoparticles, which was found to follow the classi-
cal first-order release kinetics. In addition, the release rates 
(slow release stage) of the composite nanoparticles were ac-
celerated by two orders of magnitude in a PBS solution with 
a pH value reduced from 7.4 to 1.2, which confirmed the pH-
response functions of the proposed composite nanoparticles 
that are applicable for effective treatment of the disease cells/
tissues with an acid cellular environment.     
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